|
US5807846A
(en)
|
1996-11-14 |
1998-09-15 |
Warner-Lambert Company |
Phosphonamide ACAT inhibitors
|
|
MXPA01008937A
(es)
*
|
1999-03-05 |
2004-04-05 |
Metabasis Therapeutics Inc |
Nuevos profarmacos que contienen fosforo.
|
|
US7132427B2
(en)
|
2001-06-21 |
2006-11-07 |
Ariad Pharmaceuticals, Inc. |
Quinazolines and uses thereof
|
|
US7238679B2
(en)
|
2002-12-23 |
2007-07-03 |
Ariad Pharmaceuticals, Inc. |
Heterocycles and uses thereof
|
|
CA2600797A1
(en)
*
|
2005-03-11 |
2006-09-21 |
The Regents Of The University Of Michigan |
Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
|
|
US7834023B2
(en)
*
|
2006-09-20 |
2010-11-16 |
Portola Pharmaceuticals, Inc. |
Substituted dihydroquinazolines as platelet ADP receptor inhibitors
|
|
US20080249130A1
(en)
*
|
2007-02-09 |
2008-10-09 |
Sirtris Pharmaceuticals, Inc. |
Gut microsomal triglyceride transport protein inhibitors
|
|
US8124605B2
(en)
*
|
2007-07-06 |
2012-02-28 |
Kinex Pharmaceuticals, Llc |
Compositions and methods for modulating a kinase cascade
|
|
US8563735B2
(en)
|
2008-12-05 |
2013-10-22 |
Abbvie Inc. |
Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
|
|
TWI535712B
(zh)
|
2010-08-06 |
2016-06-01 |
阿斯特捷利康公司 |
化合物
|
|
CN103370326B
(zh)
|
2010-12-16 |
2016-05-11 |
阿勒根公司 |
作为趋化因子受体调节剂的磷衍生物
|
|
EP2668180B1
(en)
*
|
2011-01-25 |
2018-08-01 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors for use in the treatment of cancer
|
|
WO2012177927A1
(en)
|
2011-06-21 |
2012-12-27 |
Mayo Foundation For Medical Education And Research |
Transgenic animals capable of being induced to delete senescent cells
|
|
WO2013052943A2
(en)
*
|
2011-10-06 |
2013-04-11 |
The Regents Of The University Of Michgian |
Small molecule inhibitors of mcl-1 and uses thereof
|
|
US9901080B2
(en)
|
2012-08-23 |
2018-02-27 |
Buck Institute For Research On Aging |
Transgenic mouse having a transgene that converts a prodrug into a cytotoxic compound in senescent cells
|
|
US20160038503A1
(en)
|
2012-11-21 |
2016-02-11 |
David Richard |
Methods and compositions useful for treating diseases involving bcl-2 family proteins with isoquinoline and quinoline derivatives
|
|
EP3689886A1
(en)
*
|
2013-01-16 |
2020-08-05 |
The Regents of The University of Michigan |
Bcl-2/bcl-xl inhibitors and their use in the treatment of cancer
|
|
RU2015149680A
(ru)
|
2013-04-21 |
2017-05-24 |
Йеда Ресеарч Энд Девелопмент Ко. Лтд. |
Агенты для подавления активности и/или снижения количества bcl-xl и/или bcl-w
|
|
US10328058B2
(en)
*
|
2014-01-28 |
2019-06-25 |
Mayo Foundation For Medical Education And Research |
Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
|
|
US20170216286A1
(en)
|
2014-01-28 |
2017-08-03 |
Mayo Foundation For Medical Education And Research |
Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
|
|
IL286427B2
(en)
|
2014-01-28 |
2024-08-01 |
Mayo Found Medical Education & Res |
Inhibitors bcl-2 anti-apoptotic protein family members for treatment of non cancer pulmonary disease or an opthalmic disease
|
|
US10550190B2
(en)
|
2014-04-04 |
2020-02-04 |
Merck Sharp & Dohme Corp. |
Phosphate based linkers for intracellular delivery of drug conjugates
|
|
EP3139942B1
(en)
|
2014-05-05 |
2019-12-18 |
Bioventures, Llc |
COMPOSITIONS AND METHODS FOR INHIBITING ANTIAPOPTOTIC Bcl-2 PROTEINS AS ANTI-AGING AGENTS
|
|
US20180000816A1
(en)
*
|
2015-02-06 |
2018-01-04 |
Unity Biotechnology, Inc. |
Use of a Heterocyclic Bcl-xL Inhibitor and Related Analogs for Removing Senescent Cells in the Treatment of Eye Diseases and Other Age-Related Conditions
|
|
WO2016127135A1
(en)
*
|
2015-02-06 |
2016-08-11 |
Unity Biotechnology, Inc. |
Compounds and uses in treatment of senescence-associated conditons
|
|
US10195213B2
(en)
|
2015-03-13 |
2019-02-05 |
Unity Biotechnology, Inc. |
Chemical entities that kill senescent cells for use in treating age-related disease
|
|
US20180199575A1
(en)
|
2015-07-15 |
2018-07-19 |
Bayer Cropscience Aktiengesellschaft |
Substituted oxotetrahydroquinolinylphosphinic acid and phosphinic acid amides or salts thereof and use thereof to increase stress tolerance in plants
|
|
CN105646587B
(zh)
*
|
2016-03-02 |
2018-03-23 |
云南中医学院 |
1,3,2‑氧氮磷杂环戊烷类化合物、制备方法及应用
|
|
WO2019001171A1
(zh)
|
2017-06-27 |
2019-01-03 |
维眸生物科技上海有限公司 |
一种含磷化合物及其制备和应用
|
|
WO2019033122A1
(en)
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
|
|
WO2019033119A1
(en)
|
2017-08-11 |
2019-02-14 |
Unity Biotechnology, Inc. |
TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
|